Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Long-Term Safety and Tolerability of Zavegepant 10 mg Nasal Spray During Concomitant Use of CGRP Monoclonal Antibodies: Results From a 1-Year Open-label Safety Trial

              Author:Berman, Gary   Mullin, Kathleen   Pavlovic, Jelena   Smith, Timothy   Croop, Robert   Madonia, Jennifer   Mosher, Linda   Hould, Jennifer   Lipton, Richard   

              Session Name:P10: Headache: Towards Precision Medicine 1  

              Topic:Headache  

              Program Number:P10.009  

              Author Institution:Clinical Research Institute , Minneapolis, MN  New England Institute for Neurology and Headache, Stamford, CT  Albert Einstein College of Medicine, Bronx, NY  StudyMetrix Research, Saint Louis, MO  Biohaven Pharmaceuticals, Wynnewood, PA  Biohaven Pharmaceuticals, New Haven, CT  Biohaven Pharmaceuticals, Wallingford, CT  

              Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52-Week, Open-Label Extension Study

              Author:Croop, Robert   Ailani, Jessica   Kudrow, David   Smith, Timothy   Lipton, Richard   Thiry, Alexandra   Jensen, Christopher   Kamen, Lisa   

              Session Name:P10: Headache: Towards Precision Medicine 1  

              Topic:Headache  

              Program Number:P10.010  

              Author Institution:Biohaven Pharmaceuticals , Wynnewood, PA  Medstar Georgetown Neurology, McLean, VA  David Kudrow MD, Los Angeles, CA  Study Metrix Research, Saint Peters, MO  Albert Einstein College of Medicine, Bronx, NY  Biohaven Pharmaceuticals, New Haven, CT  

              Safety and Tolerability of Rimegepant Every Other Day for Preventive Treatment of Migraine Plus As-Needed for Acute Treatment of Migraine: Results from A 52-Week, Open-Label Extension Phase

              Author:Lipton, Richard   Kudrow, David   Smith, Timothy   Ailani, Jessica   Goadsby, Peter   Kamen, Lisa   Thiry, Alexandra   Jensen, Christopher   Croop, Robert   

              Session Name:P12: Headache: Clinical Trials and Real World Studies 2  

              Topic:Headache  

              Program Number:P12.006  

              Author Institution:Albert Einstein College of Medicine, Bronx, NY  David Kudrow MD, Los Angeles, CA  StudyMetrix Research, Saint Louis, MO  Medstar Georgetown Neurology, McLean, VA  University of California, Los Angeles, Los Angeles, CA  Biohaven Pharmaceuticals, Inc., New Haven, CT  Biohaven Pharmaceuticals, New Haven, CT